[1]

MacroVax conjugated with GFP or fused with survivin peptides entered and activated antigen-presenting cells

Confocal image of GFP fusion inside a human dendritic cell
Flow cytometry analysis of mouse macrophages showed increased activation compared to relevant controls.
Using a blocking antibody for the immune cell receptor of interest, the specificty of the construct was confirmed.

MacroVax stimulated mouse macrophages to express activation markers:

 

MacroVax enters cells through a specific immune receptor:

 

Control
MacroVax Treated
Tumor
[2]
Secretion of pro-inflammatory cytokines
Immune Cell
[3]
Cytotoxic T cell recruitment and epitope spreading
[1]
Phagocytosis and antigen presentation

Immudicon's biologics (MacroVax) activate three distinct immune pathways:

 

[2]

MacroVax increased pro-inflammatory cytokines while surpressing anti-inflammatory cytokines

Human dendritic cells were treated for three hours, then mRNA was extracted for RT-PCR.

 

*=P <0.001, ** = P <0.01

Student’s T-test

[3]

MacroVax generates a tumor-specific T cell response in mice

Mouse T lymphocytes collected from CpG control-treated mice (left) and MacroVax-treated mice (right) spleens (3 weeks of treatment) were exposed to tumor specific antigens and analyzed for clonal expansion through cell proliferation assays.
MacroVax Treated
Control

Rapid T cell proliferation in MacroVax treated mice when exposed to tumor-specific antigens:

 

Mouse T lymphocytes collected from control, CpG/Lysate-treated, and MacroVax-treated mouse spleens (3 weeks of treatment) were exposed to tumor specific antigens and analyzed for activation via an ELISA for IFN-γ.